SCHEMBL283706

SCHEMBL283706

CC(C)(C)c1cc(NC(=O)c2cc(C(F)(F)F)ccc2F)n(Cc2ccc(F)cc2)n1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.55
MAPT P10636 3/20 0.55
MAPK1 P28482 2/20 0.55
ALDH1A1 P00352 1/20 0.54
P2RY14 Q15391 7/20 0.51
GAA P10253 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
PTGDR2 Q9Y5Y4 2/20 0.45
HTR1E P28566 1/20 0.45
S1PR3 Q99500 1/20 0.45
SLC2A1 P11166 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
LRRK2 Q5S007 1/20 0.42
SLC2A3 P11169 1/20 0.42
SLC2A4 P14672 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL283719 0.84 RET (0.41) NPSR1MAPTMAPK1ALDH1A1P2RY14
SCHEMBL283574 0.83 RET (0.40) NPSR1MAPTMAPK1ALDH1A1P2RY14
SCHEMBL283889 0.83 CNR2 (0.46)
SCHEMBL284405 0.82 CNR2 (0.45) NPSR1MAPTMAPK1P2RY14GAA
SCHEMBL283144 0.81 P2RY14 (0.48) P2RY14
SCHEMBL288529 0.81 P2RY14 (0.48) P2RY14
SCHEMBL283367 0.77 CNR2 (0.60)
SCHEMBL2813991 0.77 CNR2 (0.46) MAPTMAPK1GAASMN1; SMN2MEN1
SCHEMBL30695072 0.70 FSCN1 (0.66) PTGDR2SLC2A1LRRK2SLC2A3SLC2A4
SCHEMBL17038737 0.70 FSCN1 (0.66) PTGDR2SLC2A1LRRK2SLC2A3SLC2A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2428507-B1 Cannabinoid receptor ligands ABBVIE BAHAMAS LTD (BS) 2015-10-21 EP disclosed
EP-2896615-A1 Cannabinoid receptor ligands AbbVie Bahamas Limited (BS) 2015-07-22 EP disclosed
US-8859596-B2 Compounds as cannabinoid receptor ligands ABBVIE INC. (US) 2014-10-14 US disclosed
EP-2428507-A2 Cannabinoid receptor ligands Abbott Laboratories (US) 2012-03-14 EP disclosed
US-20100069348-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069348-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, NPY1R NPSR1 16/4885MAPT 3688/4885MAPK1 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.